RxDoctor Payments Data

Jeffrey Goldstein, MD

Gastroenterology · Rochester, NYNPI 1184677957

Payments from drug & device makers

$213,809in general payments, 2019–2025

Across 369 payments — averaging $579.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$78K
  • UCB, Inc.$75K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$40K
  • Pfizer$11K
  • Ferring Pharmaceuticals Inc.$5K
  • Redhill Biopharma Inc.$3K
  • plus $870 from 10 others
$41,180in research payments, 2019–2025

Across 3 payments — averaging $13,727 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB Biosciences Inc.$41K

What the payments were for

  • Consulting fees$29,92314%
  • Speaking & faculty fees$162,41376%
  • Travel & lodging$17,0828%
  • Food & beverage$4,3912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$213,809 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$20,076
Medicare patients
126
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase65$161,220
Humira(Cf) PenAdalimumab16$111,672
Mesalamine145$79,779
Mesalamine ErMesalamine86$27,167
LinzessLinaclotide18$20,707
TrulancePlecanatide12$10,845
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates127$7,449
Pantoprazole Sodium521$5,929
Ursodiol31$5,341
CholestyramineCholestyramine (With Sugar)71$4,511
Balsalazide Disodium20$4,392
Omeprazole96$1,549
Budesonide DrBudesonide12$1,179
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg49$1,154
Lansoprazole17$863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$77,660$181,92783 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$40,427$10,84512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →